Each Tube of Eqvalan Duo doses a 600kg Horse
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each syringe contains 7.74 g of paste and delivers:
Ivermectin 0.120 g (15.5 mg/g)
Praziquantel 0.600 g (77.5 mg/g)
Oral paste. Smooth, homogeneous orange paste.
Target species Horses
- Indications for use, specifying the target species
For the treatment of mixed cestode and nematode or arthropod infestations in horses. The following parasites of horses are sensitive to the antiparasitic effects of EQVALAN DUO, oral paste:
Strongylus vulgaris (adults and arterial larval stages)
Strongylus edentatus (adults and tissue larval stages)
Strongylus equinus (adults)
Triodontophorus spp (adults)
Craterostomum acuticaudatum (adults)
Adult and immature (intraluminal fourth-stage larvae) of small strongyles or cyathostomes, including benzimidazole-resistant strains:
Adult hairworms: Trichostrongylus axei
Adult and immature (fourth stage Larvae) pinworms: Oxyuris equi
Adult, third- and fourth-stage larvae of roundworms (ascarids): Parascaris equorum
Microfilariae of neck threadworms: Onchocerca spp
Adult intestinal threadworms: Strongyloides westeri
Adult large-mouth stomach worms: Habronema muscae
Oral and, gastric stages of bots: Gasterophilus spp
Adult and immature (inhibited fourth stage larvae) lungworms: Dictyocaulus arnfieldi
Do not use in mares producing milk for human consumption.
The product has been formulated for use in horses only. Cats, Dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also turtles and tortoises may be adversely affected by the concentration of ivermectin in this product if they are allowed to ingest spilled paste or have access to used syringes
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to macrocyclic lactones (which includes ivermectin) has been reported in Parascaris equorum in horses in the EU. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of gastro-intestinal nematodes and recommendations on how to limit further selection for resistance to anthelmintics
Special precautions for use
i. Special precautions for use in animals
Safety studies were not conducted in foals younger than 2 months of age, or in stallions, the use of Eqvalan Duo, oral paste is not recommended in these categories of animals.
ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after use.
Do not smoke, drink or eat while handling the product.
This product may cause skin and eye irritation. Therefore, the user should avoid contact of the product with the skin and the eyes. In case of contact, rinse immediately with plenty of water.
In the case of accidental ingestion or eye irritation after contact seek medical advice immediately and show the package insert or the label to the physician.
Adverse reactions (frequency and seriousness)
Some horses with heavy infections of Onchocerca spp. microfilariae have experienced oedema and pruritis following treatment; such reactions were assumed to be the result of the death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable.
In cases of heavy infestations with tapeworms, signs of mild, transient colic and loose stool may be observed.
Following administration of Eqvalan Duo, there have been rare reports of inflammation of the mouth, lip and tongue, which results in various clinical signs such as oedema, hypersalivation, erythema, tongue disorder and stomatitis. These reactions have been transitory in nature, appearing within 1 hour and abating within 24 to 48 hours following administration. In case of severe oral reactions symptomatic treatment is recommended